Australia Markets closed

3 Reasons to Buy AbbVie and 2 Reasons Not to Buy

3 Reasons to Buy AbbVie and 2 Reasons Not to Buy

2023 is expected to be an important year for AbbVie (NYSE: ABBV). The pharmaceutical company is facing its first biosimilar competition in the United States. It's big news because it involves AbbVie's monoclonal antibody blockbuster therapy, Humira, which is on track to generate a second consecutive year of $20 billion-plus in revenue in 2022.